Targets › PVRL2
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Dec 2026.
Modulator of T-cell signaling. Can be either a costimulator of T-cell function, or a coinhibitor, depending on the receptor it binds to. (UniProt, Q92692)
Open in Phaseline: the race on PVRL2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Hebei Medical University Fourth Hospital | Tuvonralimab PVRL2 (CD112R) inhibitor | PVRL2 | Phase 2 | Esophageal Squamous Cell Carcinoma (ESCC) | Dec 2026 |
Esophageal Squamous Cell Carcinoma (ESCC) (1)
–
Hebei Medical University Fourth Hospital (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.